48 results about "Occludin" patented technology

The gene for human occludin, an integral transmembrane protein specifically associated with tight junctions that functions in forming intercellular seals, is cloned, characterized, and sequenced, and the polypeptide sequence, determined. Drug delivery is enhanced by administering an effective amount of occludin inhibitors. These include peptides or antibodies that interact with occludin or occludin receptors. Also included are occludin antagonists, occludin receptor components, and mixtures thereof. In some embodiments, analogues of occludin surface loops that inhibit adhesion are employed. Administration can be local or systemic; local administration in a pharmaceutically acceptable carrier is preferred in some embodiments.

The invention discloses application of lactobacillus reuteri in preventing and relieving ulcerative colitis, and belongs to the technical field of functional microorganisms. Lactobacillus reuteri CCFM1135 can tolerate the gastrointestinal environment of a human body, significantly reduce the disease activity index during the ulcerative colitis, improve colon mucosal injury, reduce MPO activity, reduce the content of proinflammatory factors TNF-alpha, IL-6 and IFN-gamma in colon, up-regulate the transcription level of colon tight junction related proteins Claudin-3, ZO-1, ZO-2 and Occludin, up-regulate the transcription levels of colon antibacterial peptides Reg3g and Reg3b, improve the diversity of intestinal flora, and reduced the relative abundance of acinetobacter in excrement.

The invention discloses a lactobacillus plantarum for relieving ulcerative colitis and application thereof, and belongs to the technical field of functional microorganisms. The lactobacillus plantarum CCFM1117 can tolerate the gastrointestinal environment of a human body, reduce weight loss in the ulcerative colitis disease period, improve fecal characters and hemafecia conditions, relieve length shortening of the colon, improve colonic mucosal injury, reduce the content of proinflammatory factors TNF-alpha, IL-1beta, IL-6 and IFN-gamma in the colon, up-regulate the gene transcription level of colon tight junction related proteins Claudin-3, ZO-1, ZO-2 and Occludin, increase the content of short-chain fatty acid, increase the abundance of short-chain fatty acid producing bacteria Coprococcus and butyric acid producing bacteria Faecalibacterium, and improve the diversity of intestinal flora.

The invention discloses an application of lactobacillus rhamnosus to preventing and relieving ulcerative colitis, and belongs to the technical field of functional microorganisms. The lactobacillus rhamnosus can tolerate the gastrointestinal environment of a human body, significantly reduce weight loss during the period of ulcerative colitis, improve fecal traits and hematochezia, improve colon mucosal injury, reduce MPO activity, and reduce the content of proinflammatory factors TNF-alpha, IL-1beta, IL-6 and IFN-gamma in colon. The transcription levels of colon close junction related proteins Claudin-3, ZO-1, ZO-2 and Occludin, antibacterial peptides Reg3g and Reg3b and mucoprotein MUC2 are up-regulated, the abundance of short-chain fatty acid producing bacteria Coprococcus and Faecalibacterium and the content of short-chain fatty acid are improved, the abundance of beneficial bacteria Lactobacillus in intestinal tracts is increased, the abundance of the conditional pathogenic bacteria Acinetobacter is reduced, and the abundance and diversity of intestinal flora are increased.

The present invention relates generally to methods of use and compositions useful for treating skin. The composition includes a combination of saccharide isomerate extract, Myrothamnus flabellifolia extract, algae extract, mugwort (Artemisia vulgaris) extract, and [6]-paradol. This combination can be used to create topical skin compositions that reduces erythema, cools the skin, inhibits nitric oxide synthase, decreases TNF-α production, and increases the production of occludin-1.

The invention provides bifidobacterium longum subsp. Longum KLDS K5 capable of preventing and relieving symptoms of colitis, and belongs to the technical field of microorganisms. The invention further provides a preparation method of the bifidobacterium longum subsp. Longum KLDS K5. Experiments show that the bifidobacterium longum provided by the invention can tolerate the human gastrointestinal environment, relieve weight loss in the ulcerative colitis disease period, improve colonic mucosa injury and reduce MPO activity, and inhibit oxidation-related factors through iNOS and COX-2 signal pathways so as to relieve inflammatory bowel diseases; nF-kappa B p65 nuclear transfer is inhibited through a TLR4/MyD88/NF-kappa B signal channel, the expression quantity of proinflammatory factors TNF-alpha, IL-1beta, IL-6 and IL-10 in colon is reduced, the transcriptional level of colon tight connection related proteins Claudin-1, ZO-1 and Occludin and mucoprotein MUC2 is up-regulated, the intestinal flora change after DSS induction can be improved in the genus level, and the richness and diversity of the intestinal flora are improved.

The invention discloses lactobacillus reuteri CCFM1134 for preventing and relieving ulcerative colitis and application thereof, and belongs to the technical field of functional microorganisms. The lactobacillus reuteri CCFM1134 can tolerate the human gastrointestinal environment, significantly reduce weight loss during the ulcerative colitis, improve fecal traits and hematochezia, improve colon mucosal injury, reduce MPO activity, reduce the content of pro-inflammatory factors TNF-alpha, IL-1beta, IL-6 and IFN-gamma in colon, up-regulate the transcription level of colon tight junction related proteins Claudin-3, ZO-1, ZO-2 and Occludin, up-regulate transcription levels of antibacterial peptides Reg3g and Reg3b, up-regulate the transcription level of mucoprotein MUC2 in colons, and improve the diversity of intestinal flora.

The use of antagonists to JAM-1 Claudin-4 and occludin to open tight junctions. The antagonists include, by way of example antibodies and antibody fragments that bind to the proteins and small interfering nucleic acids that downregulate the mRNA encoding the proteins.

The invention belongs to the technical field of medical preparations of inorganic compounds containing ammonia, in particular to a construction method of a feces transplantation experiment piglet model, and the method is obtained by performing feces bacteria transplantation on a sterile newborn piglet. The method of the invention avoids the treatment of antibiotics or other sterilization drugs, the constructed fecal bacteria transplantation pig model has good effect with no drug residue, and the function of donor flora can be reflected more truly and reliably; the expression level of tight junction protein ZO-1 and Occludin in the empty intestine of the piglet can be improved; the development of muscular layer and gland of the intestinal wall of the piglet can be promoted; and the contentof various volatile short-chain fatty acids such as acetic acid, n-propionic acid, isobutyric acid, n-butyric acid, isovaleric acid, n-valeric acid and the like in intestinal tracts of the piglet is improved.

The invention provides tight junction protein modulators, compositions comprising the same, and uses thereof. In particular, the invention provides tight junction protein modulators that modulate the second extracellular loop of tight junction proteins, such as occludin or claudin.

The invention discloses a comprehensive buffer solution for detecting brucellosis by means of a colloidal immuno-gold immuno-filtration assay. The comprehensive buffer solution is characterized by comprising a hypotonic buffer solution, a non-ionic surfactant, an ampholytic surfactant, univalent salt ions, a metal ion chelating agent and inert occludin which is negatively charged in the hypotonic buffer solution. Compared with the prior art, the comprehensive buffer solution has the advantages of being capable of detecting a whole-blood sample, convenient to operate, accurate in result and the like.

The human Occludin protein is identified as an essential Hepatitis C Virus (HCV) cell entry factor. Occludin is shown to render murine and other non-human cells infectable with HCV and to be required for HCV—susceptibility of human cells. Associated methods for inhibiting HCV infection, transgenic animal models for HCV pathogenesis, methods of identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin, and HCV inhibitory agents are also disclosed. Kits and cell culture compositions useful for identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin are also provided.

The invention relates to a method for establishing an HCV (hepatitis C virus) cell model by utilizing tree shrew bone marrow mesenchymal stem cells, and belongs to the technical field of biological medicines. The method comprises the steps that firstly, an OCLN (occludin) lentiviral vector is adopted to infect the tree shrew bone marrow mesenchymal stem cells, then a CD81 lentiviral vector is added for further infection, then a miR-122 lentiviral vector is added for infection for 4 hours, then a fresh culture medium containing 4 mcg/mL of polybrene with 1/2 volume of a current culture medium is added, and the used culture medium is removed the next day and is replaced with the fresh culture medium for continuous culture so as to obtain the HCV (hepatitis C virus) cell model. According to the method, the cell model has the basic characteristics and the differentiation potential of the bone marrow mesenchymal stem cells and is susceptible to HCV (hepatitis C virus), HCV (hepatitis C virus) endocytosis and copy are supported, infective virus particles are produced, and new cell model resources are provided for HCV (hepatitis c virus) pathogenesis researching and drug screening.

The invention relates to the technical field of detection kits, and particularly discloses an ELISA kit for quantitatively detecting tight junction related protein Occludin. The kit comprises an elisaplate coated with an Occludin coated antibody, HRP labeled goat anti-rabbit IgG, a rabbit anti-human Occludin polyclonal antibody, a washing solution, a sample diluent, a color developing agent, a stop solution, a quality control material and a standard substance, the kit is based on the Occludin coated antibody and the goat anti-rabbit IgG, and an ELISA method for Occludin protein detection is established by adopting a double antibody sandwiching method. The kit overcomes the defects in the prior art, can be used for effectively detecting the level of Occludin protein in a serum sample, is simple, convenient and rapid to operate, has good detection accuracy and precision, high specificity, good sensitivity and good stability, and can be used for rapidly and timely helping to diagnose theillness state and monitor prognosis.

The invention provides application of pyrroloquinoline quinine active matter in prevention and control of weaned piglet diarrhea. It is found that by means of the pyrroloquinoline quinine active matter, the villus height of all sections of the small intestine of a piglet can be increased, the recess depth of the duodenum section and the jejunum section can be reduced, the expression quantity of jejunum mucosa tight junction ligandin ZO-1 and occludin can be increased, therefore, the diarrhea rate of the weaned piglet is remarkably reduced, and the feed conversion efficiency is improved. Therefore, pyrroloquinoline quinine has good application prospects in prevention, treatment and relief of generation and development of weaned piglet diarrhea.

The invention belongs to the technical field of medicines, and particularly relates to application of insulin-like growth factor 2 recombinant protein in preparation of medicines for treating ulcerative colitis. Experiments show that intraperitoneal injection of the IGF2 recombinant protein can effectively reduce the levels of colitis factors IL1 beta and TNF alpha of ulcerative colitis mice, andrecover the expression levels of insulin-like growth factor type 1 receptors, insulin-like growth factor 2 binding proteins 2 and tight junction proteins ZO1 and Occludin in colons. In addition, the colon length of the DSS model mouse can be obviously recovered through IGF2 recombinant protein administration. Results show that the IGF2 recombinant protein can reduce the inflammatory factor level in colon and improve the expression level of tight junction proteins by up-regulating the expression of IGF1R and IGF2BP2, so that the colon injury of ulcerative colitis mice is effectively prevented,and the IGF2 recombinant protein can be used for preparing a medicinal preparation for treating ulcerative colitis.

The invention discloses application of 4-methoxybenzyl alcohol in the preparation of a blood-brain barrier protective medicine. Research of the invention shows that the 4-methoxybenzyl alcohol helps reduce blood-brain permeability in the process of cerebral ischemia, reduce expressions of brain tissues, NO, iNOS and nNOS, reduce high expression of AQP4 protein and reduce the TJ major structural proteins, Occludin and Claudin-5; the cerebral ischemia can well protect the blood-brain barrier, can be made into the blood-brain barrier protective medicine and has promising clinical application prospect.

Hepatitis C virus replication at extrahepatic sites has been suggested; however, complete viral replication has only been confirmed in hepatocytes. Here we show that human adipogenic DLK-1⁺ stem cells (hADSC) freshly isolated from HCV-infected individuals contained viral transcripts, replication intermediates and viral antigens in vivo, and viral transcripts increased in supernatants upon prolonged ex vivo culture. Furthermore, naive hADSC isolated from HCV (−) individuals support complete replication of clinical isolates in vitro, and the infection is donor-nonspecific for cells and cross-genotypic for viruses. Viral infection/replication is mediated through CD81, LDL-R, SR-B1, EGFR, Apolipoprotein E, occludin, claudin-1, NPC1L1 and diacylglycerol acetyltransferase-1, and can be inhibited by anti-viral drugs. In addition, the physical properties of hADSC-propagated viral particles resemble clinical isolates more than JFH1/HCVcc, and viruses propagated by in vitro infected hADSC are infectious to primary human hepatocytes. Therefore, hADSC are an in vivo HCV reservoir and represent a novel venue of clinical virus-host interaction. hADSC can also be exploited as a physiologically relevant primary cell culture system to propagate clinical isolates.

The present invention discloses functional food for intervening chronic alcohol-induced small intestine injury and an application of the functional food. An intervention effect of chitosan oligosaccharide on the chronic alcohol-induced small intestine injury is reflected by increasing length of intestinal villi, depth of a crypt and thickness of a muscular layer and also reflected by improving gene expression quantity of a tight junction protein Occludin, reducing gene expression quantity of Claudin4, reducing D-lactic acid content and diamine oxidase activity in plasma, and reducing malondialdehyde and protein carbonyl content, thereby alleviating oxidative damages of intestinal tissues caused by alcohol; at the same time the functional food can reduce expressions of small intestine inflammatory factors IL-6, IL-1-beta and TNF-alpha and thus reduce inflammatory reactions of the small intestine tissues caused by alcohol.

The invention provides application of a tea exosome in preparation of a medicine for protecting an intestinal barrier and/or a medicine for treating an irritable bowel syndrome and the medicine for protecting the intestinal barrier and/or treating the irritable bowel syndrome. The tea exosome can be effectively absorbed by intestinal epithelial cells, and the cells are protected from being damaged by lipopolysaccharide by improving the expression of intercellular tight junction proteins ZO-1 and Occludin, so that the barrier function of the intestinal epithelial cells is protected.

The invention discloses a test strip for detecting cerebral hemorrhage 31-kDa Occludin after thrombolysis. The test strip is prepared by sequentially pasting a sample pad, a reaction pad, a nitrocellulose membrane and an absorption pad on a PVC bottom card, wherein the nitrocellulose membrane adopts a goat anti-rabbit antibody line as a quality control line C, an IgG capture antibody of rabbit anti-31-kDa Occludin protein is adopted as a detection line T on the nitrocellulose membrane, the reaction pad is sprayed with a Fe3O4 nano-enzyme-anti-31-kDa Occludin protein antibody coupling compound,and the reaction pad is pretreated by adopting 1-2% of Casein-PBS and 0.5-1% of Triton X-100. The test strip is good in specificity and high in sensitivity, is a prediction product which is low in price, high in accuracy, rapid in detection and simple to operate and is used for predicting cerebral hemorrhage risk after cerebral apoplexy thrombolysis or thrombus taking, and has good market application value.

The invention belongs to the field of compositions for regulating human intestinal microecology, and particularly relates to a prebiotic composition and application thereof in inhibiting pathogenic bacterium adhesion and improving intestinal epithelial cell barrier. The prebiotic composition comprises 5 to 30 parts of 2 '-fucosyllactose, 0 to 20 parts of 3-fucosyllactose, 10 to 100 parts of fructo-oligosaccharide and 10 to 100 parts of galactooligosaccharide, and the prebiotic composition formed by compounding 2'-FL, 3-FL, FOS and GOS according to a specific ratio not only can effectively inhibit the adhesion of Escherichia coli, but also can inhibit the growth of the Escherichia coli. And by promoting expression of intestinal epithelial cell tight junction proteins ZO-1, Occludin and Claudin-1, the barrier function of the intestinal tract is directly enhanced, and the intestinal tract barrier injury induced by pathogens is inhibited.